Important note: Information in this article was accurate in December 2004. The state of the art may have changed since the publication date.
 |
AIDSWEEKLY Plus; Monday, December 27, 2004
Staff Medical Writers
According to recent research from France, "Predictive factors of the virologic Success of the use of lopinavir/ritonavir (LPV/r) in HIV-infected children are unknown, especially in children who have been pretreated with protease inhibitors (PIs).
"This longitudinal, single-center, observational study included 69 children (21 PI-naive and 48 PI-experienced) who had received LPV/r for at least 3 months. The mean(±SD) age was 10.3±4.8 years, and the mean baseline of CD4 percentage and HIV-1 RNA was 14.9%±9.8% and 4.8±1.05 log10 copies/mL, respectively. The mean duration of follow-up was 16.5±8.3 months."
"At 6, 12, and 18 months," said C. Delaugerre and coworkers, "52%, 57%, and 49% of all children, respectively, had a viral load less than 50 copies/mL. The risk of virologic failure, defined as 2 consecutive viral loads greater than 1000 copies/mL, was significantly higher when the children were previously treated with PIs and when the baseline LPV mutation score exceeded 3 mutations."
"In the pretreated children, the ratio of the plasma LPV maximal concentration to the baseline LPV score mutation was also associated with failure, independently of resistance score," scientists reported.
"Finally," Delaugerre continued, "in children failing an LPV-containing regimen, accumulation of additional PI-associated resistance mutations was evidenced in viral isolates from children with prior PI treatment, even with viral replication levels less than 10,000 copies/mL."
"In pretreated children, LPV plasma levels should be optimized in an attempt to achieve sufficient drug concentrations to overcome the resistance level," the authors concluded.
Delaugerre and colleagues published their study in Journal of Acquired Immune Deficiency Syndromes (Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2004 Oct 1;37(2):1269-1275.
For additional information, contact C. Delaugerre, Hop Necker Enfants Malad, Service Virology, EA 3620, 149 Rue Sevres, F-75015 Paris, France.
Publisher contact information for the Journal of Acquired Immune Deficiency Syndromes is: Lippincott Williams & Wilkins, 530 Walnut St., Philadelphia, PA 19106-3621, USA.
The information in this article comes under the major subject areas of HIV/AIDS, Pediatrics, Lopinavir/Ritonavir, Protease Inhibitors and Virologic Failure.
This article was prepared by AIDS Weekly editors from staff and other reports.
Reference
Delaugerre C, Teglas JP, Treluyer JM, et al., "Predictive Factors of Virologic Success in HIV-1–Infected Children Treated With Lopinavir/Ritonavir", J Acquir Immune Defic Syndr. 2004 Oct 1;37(2):1269-1275.
PubMED Related articles Search
041227
AW041211
Copyright © 2004 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright © 1980,2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.